Background: The NCCN has recently endorsed the stratification of intermediate-risk prostate cancer (IR-PCa) into favorable and unfavourable subgourps, and recommend the addition of androgen deprivation therapy (ADT) to radiotherapy (RT) for unfavorable IR-PCa. Recently, more accurate prognostication was demonstrated by integrating a
Image-guided radiation therapy (IGRT) represents a primary treatment modality for localized prostate cancer (1) . Prospective evidence supports combination androgen deprivation therapy (ADT) with IGRT to both improve local control (i.e. radiosensitization) and target occult metastases (2) , reducing the disease-specific mortality in high-risk prostate cancer (3, 4) . However, the benefit of systemic intensification is debatable for intermediate-risk prostate cancer (IR-PCa), especially when treated with dose-escalated IGRT (DE-IGRT). The NCCN now endorses factoring in additional factors to subclassify an unfavorable IR-PCa subgroup, who are at higher risk of metastatic relapse and prostate cancer-specific mortality (5) , and therefore more likely to benefit from combined modality treatments such as ADT with RT (4, 6, 7).
Comprehensive molecular profiling of IR-PCa has revealed multiple genomic features of aggression within tumor foci harboring the same histomorphological grade (8, 9) , highlighting the role of genomics for enhanced prognostication beyond conventional indices. On this note, a clinically approved RNA-based 22-gene genomic classifier (GC, [Decipher, GenomeDx BioSciences]) has been validated as a stratification tool for risk of metastatic relapse, PCa-specific mortality, and predicting response to postoperative RT (10) (11) (12) (13) . Additionally, the 22-gene GC has been included in a novel clinicogenomic classification that was proposed to represent a more precise method for risk-stratifying localized PCa (14) .
Here, we evaluate the validity of the 22 
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Materials and methods
Study Cohort
After obtaining institutional approval (XXXXX), we queried our prospective registry During the study period, diagnostic systematic biopsies consist of 11-12 samples obtained under transrectal ultrasound guidance. Pathology database was crossreferenced to identify those who had prostate core biopsies paraffin-embedded blocks available in-house for genomic characterization. Clinical and genomic data were collected and added to the GenomeDx prostate cancer genomic resource information database (GRID TM , NCT02609269). This is therefore an unpublished cohort with complete clinical and genomic annotation.
Specimen Collection and Processing
Hematoxylin and eosin stained slides of diagnostic prostate biopsies were centrally Decipher CLIA-certified commercial platform, as previously described (10) . Microarray quality control was performed using the Affymetrix Power Tools packages (16) .
Probeset summarization and normalization was subsequently performed using the single channel array normalisation (SCAN) algorithm (17) .
Calculation of GC score and NCCN subclassification
The 22-gene GC score was determined from the Decipher prostate cancer classifier assay (GenomeDx Biosciences Laboratory, San Diego, California) as previously described (10, 15, 18) . Briefly, GC was calculated based on a locked random forest model to produce a score between 0 and 1. Formerly established cut-points of 0.45 and 0.6 for GC were used for categorical analyses. As per NCCN-endorsed subclassification, unfavorable IR-PCa was defined as any patient with a primary Figure 1) . Interestingly, the combinatorial NCCN subclassification and GC as per the new clinicogenomic risk grouping system (14) yielded a comparable stratification of high-risk cases to using the GC alone (N = 12 (9.9%), Table 1 ).
We 
Conclusions
We report on the robust prediction of biochemical failure and metastasis occurrence using a clinically available GC test in IR-PCa patients who were treated with single modality DE-IGRT. Our study supports the need to evaluate GC in a prospective fashion, as we envisage that the clinicogenomic model could be utilized to personalize treatment intensification with combinatorial ADT and DE-IGRT for IR-PCa patients. Figure S1 . 1.33 (1.08-1.66 1.33 (1.08-1.64 1.84 (1.18-3 
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